Clinical trial

Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer

NCT06513364

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention WH002 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record paclitaxel injection Normalized identity: paclitaxel InjectionView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-09-10

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

WH002DRUG

paclitaxel injectionDRUG · verified · RxNorm: paclitaxel Injection

Sponsors & collaborators

Beijing Wehand-Bio Pharmaceutical Co., Ltdlead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciencescollaborator

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06513364 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.